Followers | 0 |
Posts | 1,934 |
Boards Moderated | 0 |
Alias Born | 03/04/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RBII the CBD only Cannophen variant dovetails neatly with the segment of Rising Biosciences business model specializing in physician and behavioral health facilities management for the treatment of substance abuse and mental health disorders.
$RBII The new CBD-only variant of Cannophen leverages unique opportunities for Rising Biosciences in two arenas:
Cannabidiol (CBD) is a non-psychogenic distillate derived from the stalks of the hemp plant. Mainstream consumers worldwide are increasingly becoming avid enthusiasts of the health and wellness benefits of CBD with sales of products containing the compound projected to exceed $5 Billion in 2019.
$RBII closed up 22.73 percent on Wednesday, July 17, 2019, on 1.19 times normal volume.
GM $RBII
Severely Undervalued Biotech Cannabis company that should be trading multiple pennies. $RBII
UP 16% $RBII Keep this one on watch.
$PAOG gettting some good exposure.
$PAOG stil gaining critical awareness.
$15 Billion anxiety treatment market, what an opportunity for $RBII
$RBII is committed to fighting the opioid epidemic. Its the largest illicit drug epidemic to hit us in USA history.
$RBII something big is going on behind the scenes I think.
$PAOG sitting on a gold mine with Cannophen capsules.
$PAOG looking very solid. News must be coming soon.
Release of Cannophen is a big move in this sector. $PAOG
I'm expecting we will get more communication from exec team soon. $PAOG
$RBII long and strong here.
$RBII massive need for addictions treatment in the USA right now. More than ever due to the opiod crisis. Cannophen could be the answer. $RBII
$RBII this treatment center will bring in $10 million in inpatient revenue and $5mil in outpatient revs.
Follow $RBII on Twitter for LIVE company updates: https://www.twitter.com/risingindiausa
I think we will see a huge run for $RBII when Cannophen has completed the Pilot production run.
Cannabis Cup is the worlds premier cannabis event. Great for $RBII
$RBII Cannophen Pilot Production Run BEGINS...cant wait for more update
$RBII is gettin warm up.
Cannophen features a 1 to 1 CBD and THC distillate for rabid absorbtion and maxium effectiveness of the active compounds. $PAOG
$PAOG once they launch the CBD only variant of Cannophen, they will be able to sell it online.
Karl Riedel seems like seriously busy here. He has major marketing chops and it seems we could see the fruit of that very soon. $PAOG
Looking for a bounce today after $PAOG closed down 7.69 percent on Tuesday, July 16, 2019, on 4.18 times normal volume.
$RBII taking the CBD to mainstream with CBD only variant of Cannophen Capsules and Vape Cartridges
$RBII on MoneyTV, the featured spot starts at around 3:05 https://vimeo.com/344940684
$RBII I'm thinking this could be the start of a great week here.
$RBII SOLID COMPANY "Cannophen™ is Rising Biosciences’ flagship product. Cannophen™ oral capsules and vape cartridges have been developed using strict standards set forward by the pharmaceutical compounding industry. Cannophen ™ features an alternative delivery system for rapid reception of the full metabolic benefits of beneficial compounds derived from the hemp plant. On June 8th of this year, the Company debuted Cannophen™ capsules and vape cartridges featuring 1 to 1 CBD and THC distillates at the High Times Cannabis Cup, Michigan, to an enthusiastic industry reception."
Cannophen Capsules and Vape Cartridges will drive some major revenues. $RBII
Please check out and follow our new Twitter account: https://twitter.com/RisingBioscien1 About Rising Biosciences, Inc.
Adding a CBD only product grants access to a global mainstream market demand that is growing in exponential fashion with no signs of slowing in the near-term future, according to many analysts. The Company will be able to deploy a deeper arsenal of marketing and distribution solutions for a CBD only product, including avenues such as online sales platforms.
This is the same premium Cannophen that we debuted in June, with the full spectrum of CBD distillates engineered to be rapidly bioactivated by the body, only this variant is non-THC.
I am thrilled that we can now launch our CBD only variant of Cannophen, exclaimed Art Hall, CEO of Rising Biosciences.
CBD only variant of Cannophen Capsules and Vape Cartridges has entered into an initial production run. $RBII
$RBII closed up 4.76 percent on yesterday, on 1.28 times normal volume.
Great developments here. $PAOG